Share：
Share this content in WeChat
X
[Chinese][PDF]82587
• Clinical Article •
The study of left heart structure and function difference in hypertrophic cardiomyopathy patients with or without atrial fibrillation by MRI
XU Min  SUN Zhaonan  WANG Xuchao  XU Chang  WANG Wei 

Cite this article as: Xu M, Sun ZN, Wang XC, et al. The study of left heart structure and function difference in hypertrophic cardiomyopathy patients with or without atrial fibrillation by MRI. Chin J Magn Reson Imaging, 2019, 10(11): 821-825. DOI:10.12015/issn.1674-8034.2019.11.005.


[Abstract] Objective: To explore the differences of left heart structure and function in hypertrophic cardiomyopathy patients with or without atrial fibrillation using cardiac magnetic resonance imaging, and provide a basis for clinical active treatment.Materials and Methods: Retrospective analysis of 109 hypertrophic cardiomyopathy patients who underwent 1.5 T cardiac magnetic resonance and were diagnosed in our hospital, according to the presence of atrial fibrillation, were divided into atrial fibrillation group (n=21) and non-atrial fibrillation group (n=88), comparing the two groups of patients with magnetic resonance parameters representing left heart structure and function, multivariate logistic regression analysis was performed on the left ventricle statistically significant parameters, to obtain the relevant influencing factors of atrial fibrillation.Results: LAAPD, age, LGE% in hypertrophic cardiomyopathy patients with atrial fibrillation was higher than hypertrophic cardiomyopathy patients without atrial fibrillation (P<0.05). LVEF and LVPFR in patients with atrial fibrillation was lower than patients without atrial fibrillation (P<0.05). The other parameters were no significant difference between the two groups (P>0.05). In multivariate logistic regression analysis, hypertrophic cardiomyopathy patients with atrial fibrillation was associated with LVPFR (P=0.011) and LGE% (P=0.005).Conclusions: The LVPFR and LVEF, age, LAAPD and LGE% are difference in hypertrophic cardiomyopathy patients with or without atrial fibrillation. Inside, LVPFR and LGE% were predictors of hypertrophic cardiomyopathy patients with AF.
[Keywords] cardiomyopathy, hypertrophic；atrial fibrillation；magnetic resonance imaging

XU Min Department of Magnetic Resonance, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China

SUN Zhaonan Department of Magnetic Resonance, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China

WANG Xuchao Department of Magnetic Resonance, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China

XU Chang Department of Magnetic Resonance, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China

WANG Wei * Department of Magnetic Resonance, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China

*Correspondence to: Wang W, E-mail: 1391082196@qq.com

Conflicts of interest   None.

Received  2019-06-26
DOI: 10.12015/issn.1674-8034.2019.11.005
Cite this article as: Xu M, Sun ZN, Wang XC, et al. The study of left heart structure and function difference in hypertrophic cardiomyopathy patients with or without atrial fibrillation by MRI. Chin J Magn Reson Imaging, 2019, 10(11): 821-825. DOI:10.12015/issn.1674-8034.2019.11.005.

[1]
Rowin EJ, Orfanos A, Estes NAM, et al. Occurrence and natural history of clinically silent episodes of atrial fibrillation in hypertrophic cardiomyopathy. Am J Cardiol, 2017, 119(11): 1862-1865.
[2]
Pennell DJ. Cardiovascular magnetic resonance. Circulation, 2010, 121(5): 692-705.
[3]
Kim KJ, Choi HM, Yoon YE, et al. Left atrial mechanical function and global strain in hypertrophic cardiomyopathy. PloS One, 2016, 11(6): e0157433.
[4]
Dzeshka MS, Lip GY, Snezhitskiy V. Cardiac fibrosis in patients with atrial fibrillation: mechanisms and clinical implications. J Am Coll Cardiol, 2015, 66(8): 943-959.
[5]
Elliott PM, Anastasakis A, Borger Ma, et al. 2014 esc guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the european society of cardiology (esc). Eur Heart J, 2014, 35(39): 2733-2779.
[6]
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18(11): 1609-1678.
[7]
Liu DT, Ma XH, Liu JY, et al. Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy: comparison of diagnostic performance in myocardial fibrosis between gadobutrol and gadopentetate dimeglumine. Int J Cardiovasc Imaging, 2017, 33(8): 1191-1200.
[8]
Lohit G, Manasvi G, Syed R, et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management. Heart Fail Rev, 2019, 24(2): 189-197.
[9]
王辉，徐磊，贺毅，等．心脏磁共振评价心尖肥厚型心肌病患者左心房室结构、功能及其相关性研究．磁共振成像, 2019, 10(6): 415-419
[10]
Bonow RO, Frederick TM, Bacharach SL, et al. Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. Am J Cardiol, 1983, 51(8): 1386-1391.
[11]
Pujadas S, Vidal-Perez R, Hidalgo A, et al. Correlation between myocardial fibrosis and the occurrence of atrial fibrillation in hypertrophic cardiomyopathy: a cardiac magnetic resonance imaging study. Eur J Radiol, 2010, 75(2): e88-91.
[12]
Graça B, Ferreira MJ, Donato P, et al. Cardiovascular magnetic resonance imaging assessment of diastolic dysfunction in a population without heart disease: a gender-based study. Eur Radiol, 2014, 24(1): 52-59 .
[13]
Kudelka AM, Turner DA, Liebson PR, et al. Comparison of cine magnetic resonance imaging and Doppler echocardiography for evaluation of left ventricular diastolic function. Am J Cardiol, 1997, 80(3): 384-386.
[14]
Papavassiliu T, Germans T, Flüchter S, et al. CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation. J Cardiovasc Magn Reson, 2009, 11(1): 1-9.
[15]
Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol, 2004, 43(12): 2260-2264 .
[16]
Konno T, Hayashi K, Fujino N, et al. High sensitivity of late gadolinium enhancement for predicting microscopic myocardial scarring in biopsied specimens in hypertrophic cardiomyopathy. PLoS One, 2014, 9(7): e101465.
[17]
Weng Z, Yao J, Chan RH, et al. Prognostic value of LGE-CMR in HCM: a meta-analysis. JACC Cardiovasc Imaging, 2016, 9(12): 1392-1402.
[18]
Tian H, Cui J, Yang C, et al. Left ventricular remodeling in hypertrophic cardiomyopathy patients with atrial fibrillation. BMC Cardiovasc Disord, 2018, 18(1): 207.
[19]
Klopotowski M, Kwapiszewska A, Kukula K, et al. Clinical and echocardiographic parameters as risk factors for atrial fibrillation in patients with hypertrophic cardiomyopathy. Clin Cardiol, 2018, 41(10): 1336-1340.
[20]
Ellims AH, Iles LM, Ling LH, et al. Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction. J Cardiovasc Magn Reson, 2012, 14(1): 76.
[21]
Philipson DJ, Rader F. Risk factors for atrial fibrillation in hypertrophic cardiomyopathy. Clin Cardiol, 2019, 6: DOI: .
[22]
Olivotto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation, 2001, 104(21): 2517-2524.

PREV Application of magnetic resonance HASTE and TRUE-FISP sequences in diagnosis of fetal cleft lip and palate
NEXT Preliminary study on correlation between gray level co-occurrence matrix texture analysis based on whole tumor volume measurement ADC image and Ki-67 expression in endometrial cancer
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn